August 2024

Starting Aug. 1, we’ll change how we cover brand-name Copaxone 40 mg

Starting Aug. 1, 2024, Blue Cross Blue Shield of Michigan and Blue Care Network will change how we cover brand-name Copaxone^® (glatiramer acetate) 40 mg, a medication commonly used to treat relapsing forms of multiple sclerosis.

Members can continue to fill their prescription with generic glatiramer acetate (Copaxone^®, Glatopa^®). A new prescription may be needed.

The following table summarizes the changes for members if they continue to fill their prescription with brand-name Copaxone^® 40 mg.

Affected drug list or benefit plan	Change for brand-name Copaxone^® 40 mg starting Aug. 1
Custom Select Drug List	Drug not covered (Member will be responsible for the entire cost of the prescription.)
Preferred Drug List
Closed Benefit
Custom Drug List	Member may pay more (Higher cost share)
Clinical Drug List	Member may pay more (Higher cost share)

We’ve been sending letters to notify affected members, their groups and their health care providers about these changes.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2023 American Medical Association. All rights reserved.